10.56 0.56 (5.6%) | 07-26 15:55 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 13.21 ![]() |
1-year : | 15.42 ![]() |
Resists | First : | 11.31 ![]() |
Second : | 13.21 ![]() |
Pivot price | 9.01 ![]() |
|||
Supports | First : | 7.98 ![]() |
Second : | 5.92 |
MAs | MA(5) : | 9.7 ![]() |
MA(20) : | 8.81 ![]() |
MA(100) : | 10.48 ![]() |
MA(250) : | 16.05 ![]() |
|
MACD | MACD : | 0.2 ![]() |
Signal : | 0 ![]() |
%K %D | K(14,3) : | 73.9 ![]() |
D(3) : | 68.1 ![]() |
RSI | RSI(14): 57.3 ![]() |
|||
52-week | High : | 31.64 | Low : | 5.92 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SER ] has closed below upper band by 17.6%. Bollinger Bands are 5.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 10.91 - 10.96 | 10.96 - 11 |
Low: | 9.67 - 9.71 | 9.71 - 9.76 |
Close: | 10.48 - 10.56 | 10.56 - 10.63 |
Thu, 18 Jul 2024
Serina Therapeutics Welcomes New Senior VP to Advance Drug Development - TipRanks
Thu, 18 Jul 2024
Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation - StockTitan
Fri, 12 Jul 2024
Serina Therapeutics COO Retirement and Consulting Agreement - TipRanks
Fri, 17 May 2024
Enable Injections & Serina Partner to Develop Novel Parkinson’s Treatment - - HIT Consultant
Tue, 14 May 2024
Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NYSE
|
|
Sector:
|
|
Industry:
|
|
Shares Out | 0 (M) |
Shares Float | 0 (M) |
Held by Insiders | 0 (%) |
Held by Institutions | 0 (%) |
Shares Short | 0 (K) |
Shares Short P.Month | 0 (K) |
EPS | 0 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | 0 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | 0 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | 0 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |